PubMed:19176376 JSONTXT

{"project":"sentences","denotations":[{"id":"TextSentencer_T1","span":{"begin":0,"end":119},"obj":"Sentence"},{"id":"TextSentencer_T2","span":{"begin":120,"end":184},"obj":"Sentence"},{"id":"TextSentencer_T3","span":{"begin":185,"end":341},"obj":"Sentence"},{"id":"TextSentencer_T4","span":{"begin":342,"end":426},"obj":"Sentence"},{"id":"TextSentencer_T5","span":{"begin":427,"end":648},"obj":"Sentence"},{"id":"TextSentencer_T6","span":{"begin":649,"end":872},"obj":"Sentence"},{"id":"TextSentencer_T7","span":{"begin":873,"end":1162},"obj":"Sentence"},{"id":"TextSentencer_T8","span":{"begin":1163,"end":1289},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":119},"obj":"Sentence"},{"id":"T2","span":{"begin":120,"end":184},"obj":"Sentence"},{"id":"T3","span":{"begin":185,"end":341},"obj":"Sentence"},{"id":"T4","span":{"begin":342,"end":426},"obj":"Sentence"},{"id":"T5","span":{"begin":427,"end":648},"obj":"Sentence"},{"id":"T6","span":{"begin":649,"end":872},"obj":"Sentence"},{"id":"T7","span":{"begin":873,"end":1162},"obj":"Sentence"},{"id":"T8","span":{"begin":1163,"end":1289},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design.\nThe tumor antigen NY-ESO-1 is a promising cancer vaccine target. We describe here a novel HLA-B7-restricted NY-ESO-1 epitope, encompassing amino acids 60-72 (APRGPHGGAASGL), which is naturally presented by melanoma cells. The tumor epitope bound to HLA-B7 by bulging outward from the peptide-binding cleft. This bulged epitope was not an impediment to T-cell recognition, however, because four of six HLA-B7(+) melanoma patients vaccinated with NY-ESO-1 ISCOMATRIX vaccine generated a potent T-cell response to this determinant. Moreover, the response to this epitope was immunodominant in three of these patients and, unlike the T-cell responses to bulged HLA class I viral epitopes, the responding T cells possessed a remarkably broad TCR repertoire. Interestingly, HLA-B7(+) melanoma patients who did not receive the NY-ESO-1 ISCOMATRIX vaccine rarely generated a spontaneous T-cell response to this cryptic epitope, suggesting a lack of priming of such T cells in the natural anti-NY-ESO-1 response, which may be corrected by vaccination. Together, our results reveal several surprising aspects of antitumor immunity and have implications for cancer vaccine design."}

{"project":"DisGeNET","denotations":[{"id":"T0","span":{"begin":65,"end":78},"obj":"gene:404663"},{"id":"T1","span":{"begin":97,"end":103},"obj":"disease:C0006826"},{"id":"T2","span":{"begin":65,"end":78},"obj":"gene:404663"},{"id":"T3","span":{"begin":97,"end":103},"obj":"disease:C1306459"},{"id":"T4","span":{"begin":138,"end":146},"obj":"gene:1485"},{"id":"T5","span":{"begin":162,"end":168},"obj":"disease:C1306459"},{"id":"T6","span":{"begin":138,"end":146},"obj":"gene:1485"},{"id":"T7","span":{"begin":162,"end":168},"obj":"disease:C0006826"},{"id":"T8","span":{"begin":138,"end":146},"obj":"gene:246100"},{"id":"T9","span":{"begin":162,"end":168},"obj":"disease:C0006826"},{"id":"T10","span":{"begin":124,"end":137},"obj":"gene:404663"},{"id":"T11","span":{"begin":162,"end":168},"obj":"disease:C1306459"},{"id":"T12","span":{"begin":124,"end":137},"obj":"gene:404663"},{"id":"T13","span":{"begin":162,"end":168},"obj":"disease:C0006826"},{"id":"T14","span":{"begin":138,"end":146},"obj":"gene:246100"},{"id":"T15","span":{"begin":162,"end":168},"obj":"disease:C1306459"},{"id":"T16","span":{"begin":228,"end":236},"obj":"gene:1485"},{"id":"T17","span":{"begin":326,"end":334},"obj":"disease:C0025202"},{"id":"T18","span":{"begin":228,"end":236},"obj":"gene:246100"},{"id":"T19","span":{"begin":326,"end":334},"obj":"disease:C0025202"}],"relations":[{"id":"R1","pred":"associated_with","subj":"T0","obj":"T1"},{"id":"R2","pred":"associated_with","subj":"T2","obj":"T3"},{"id":"R3","pred":"associated_with","subj":"T4","obj":"T5"},{"id":"R4","pred":"associated_with","subj":"T6","obj":"T7"},{"id":"R5","pred":"associated_with","subj":"T8","obj":"T9"},{"id":"R6","pred":"associated_with","subj":"T10","obj":"T11"},{"id":"R7","pred":"associated_with","subj":"T12","obj":"T13"},{"id":"R8","pred":"associated_with","subj":"T14","obj":"T15"},{"id":"R9","pred":"associated_with","subj":"T16","obj":"T17"},{"id":"R10","pred":"associated_with","subj":"T18","obj":"T19"}],"namespaces":[{"prefix":"gene","uri":"http://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"disease","uri":"http://purl.bioontology.org/ontology/MEDLINEPLUS/"}],"text":"A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design.\nThe tumor antigen NY-ESO-1 is a promising cancer vaccine target. We describe here a novel HLA-B7-restricted NY-ESO-1 epitope, encompassing amino acids 60-72 (APRGPHGGAASGL), which is naturally presented by melanoma cells. The tumor epitope bound to HLA-B7 by bulging outward from the peptide-binding cleft. This bulged epitope was not an impediment to T-cell recognition, however, because four of six HLA-B7(+) melanoma patients vaccinated with NY-ESO-1 ISCOMATRIX vaccine generated a potent T-cell response to this determinant. Moreover, the response to this epitope was immunodominant in three of these patients and, unlike the T-cell responses to bulged HLA class I viral epitopes, the responding T cells possessed a remarkably broad TCR repertoire. Interestingly, HLA-B7(+) melanoma patients who did not receive the NY-ESO-1 ISCOMATRIX vaccine rarely generated a spontaneous T-cell response to this cryptic epitope, suggesting a lack of priming of such T cells in the natural anti-NY-ESO-1 response, which may be corrected by vaccination. Together, our results reveal several surprising aspects of antitumor immunity and have implications for cancer vaccine design."}

{"project":"DisGeNET5_gene_disease","denotations":[{"id":"19176376-2#43#51#gene1485","span":{"begin":228,"end":236},"obj":"gene1485"},{"id":"19176376-2#43#51#gene246100","span":{"begin":228,"end":236},"obj":"gene246100"},{"id":"19176376-2#141#149#diseaseC0025202","span":{"begin":326,"end":334},"obj":"diseaseC0025202"}],"relations":[{"id":"43#51#gene1485141#149#diseaseC0025202","pred":"associated_with","subj":"19176376-2#43#51#gene1485","obj":"19176376-2#141#149#diseaseC0025202"},{"id":"43#51#gene246100141#149#diseaseC0025202","pred":"associated_with","subj":"19176376-2#43#51#gene246100","obj":"19176376-2#141#149#diseaseC0025202"}],"text":"A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design.\nThe tumor antigen NY-ESO-1 is a promising cancer vaccine target. We describe here a novel HLA-B7-restricted NY-ESO-1 epitope, encompassing amino acids 60-72 (APRGPHGGAASGL), which is naturally presented by melanoma cells. The tumor epitope bound to HLA-B7 by bulging outward from the peptide-binding cleft. This bulged epitope was not an impediment to T-cell recognition, however, because four of six HLA-B7(+) melanoma patients vaccinated with NY-ESO-1 ISCOMATRIX vaccine generated a potent T-cell response to this determinant. Moreover, the response to this epitope was immunodominant in three of these patients and, unlike the T-cell responses to bulged HLA class I viral epitopes, the responding T cells possessed a remarkably broad TCR repertoire. Interestingly, HLA-B7(+) melanoma patients who did not receive the NY-ESO-1 ISCOMATRIX vaccine rarely generated a spontaneous T-cell response to this cryptic epitope, suggesting a lack of priming of such T cells in the natural anti-NY-ESO-1 response, which may be corrected by vaccination. Together, our results reveal several surprising aspects of antitumor immunity and have implications for cancer vaccine design."}

{"project":"DisGeNet-2017-sample","denotations":[{"id":"T2863","span":{"begin":228,"end":236},"obj":"gene:1485"},{"id":"T2864","span":{"begin":326,"end":334},"obj":"disease:C0025202"}],"relations":[{"id":"R1","pred":"associated_with","subj":"T2863","obj":"T2864"},{"id":"R2","pred":"associated_with","subj":"T2863","obj":"T2864"}],"namespaces":[{"prefix":"gene","uri":"http://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"disease","uri":"http://purl.bioontology.org/ontology/MEDLINEPLUS/"}],"text":"A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design.\nThe tumor antigen NY-ESO-1 is a promising cancer vaccine target. We describe here a novel HLA-B7-restricted NY-ESO-1 epitope, encompassing amino acids 60-72 (APRGPHGGAASGL), which is naturally presented by melanoma cells. The tumor epitope bound to HLA-B7 by bulging outward from the peptide-binding cleft. This bulged epitope was not an impediment to T-cell recognition, however, because four of six HLA-B7(+) melanoma patients vaccinated with NY-ESO-1 ISCOMATRIX vaccine generated a potent T-cell response to this determinant. Moreover, the response to this epitope was immunodominant in three of these patients and, unlike the T-cell responses to bulged HLA class I viral epitopes, the responding T cells possessed a remarkably broad TCR repertoire. Interestingly, HLA-B7(+) melanoma patients who did not receive the NY-ESO-1 ISCOMATRIX vaccine rarely generated a spontaneous T-cell response to this cryptic epitope, suggesting a lack of priming of such T cells in the natural anti-NY-ESO-1 response, which may be corrected by vaccination. Together, our results reveal several surprising aspects of antitumor immunity and have implications for cancer vaccine design."}

{"project":"UBERON-AE","denotations":[{"id":"PD-UBERON-AE-B_T1","span":{"begin":432,"end":438},"obj":"http://purl.obolibrary.org/obo/UBERON_0018306"},{"id":"PD-UBERON-AE-B_T2","span":{"begin":770,"end":776},"obj":"http://purl.obolibrary.org/obo/UBERON_0018306"}],"text":"A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design.\nThe tumor antigen NY-ESO-1 is a promising cancer vaccine target. We describe here a novel HLA-B7-restricted NY-ESO-1 epitope, encompassing amino acids 60-72 (APRGPHGGAASGL), which is naturally presented by melanoma cells. The tumor epitope bound to HLA-B7 by bulging outward from the peptide-binding cleft. This bulged epitope was not an impediment to T-cell recognition, however, because four of six HLA-B7(+) melanoma patients vaccinated with NY-ESO-1 ISCOMATRIX vaccine generated a potent T-cell response to this determinant. Moreover, the response to this epitope was immunodominant in three of these patients and, unlike the T-cell responses to bulged HLA class I viral epitopes, the responding T cells possessed a remarkably broad TCR repertoire. Interestingly, HLA-B7(+) melanoma patients who did not receive the NY-ESO-1 ISCOMATRIX vaccine rarely generated a spontaneous T-cell response to this cryptic epitope, suggesting a lack of priming of such T cells in the natural anti-NY-ESO-1 response, which may be corrected by vaccination. Together, our results reveal several surprising aspects of antitumor immunity and have implications for cancer vaccine design."}

{"project":"performance-test","denotations":[{"id":"PD-UBERON-AE-B_T1","span":{"begin":379,"end":386},"obj":"http://purl.obolibrary.org/obo/UBERON_0018306"},{"id":"PD-UBERON-AE-B_T2","span":{"begin":432,"end":438},"obj":"http://purl.obolibrary.org/obo/UBERON_0018306"},{"id":"PD-UBERON-AE-B_T3","span":{"begin":770,"end":776},"obj":"http://purl.obolibrary.org/obo/UBERON_0018306"}],"text":"A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design.\nThe tumor antigen NY-ESO-1 is a promising cancer vaccine target. We describe here a novel HLA-B7-restricted NY-ESO-1 epitope, encompassing amino acids 60-72 (APRGPHGGAASGL), which is naturally presented by melanoma cells. The tumor epitope bound to HLA-B7 by bulging outward from the peptide-binding cleft. This bulged epitope was not an impediment to T-cell recognition, however, because four of six HLA-B7(+) melanoma patients vaccinated with NY-ESO-1 ISCOMATRIX vaccine generated a potent T-cell response to this determinant. Moreover, the response to this epitope was immunodominant in three of these patients and, unlike the T-cell responses to bulged HLA class I viral epitopes, the responding T cells possessed a remarkably broad TCR repertoire. Interestingly, HLA-B7(+) melanoma patients who did not receive the NY-ESO-1 ISCOMATRIX vaccine rarely generated a spontaneous T-cell response to this cryptic epitope, suggesting a lack of priming of such T cells in the natural anti-NY-ESO-1 response, which may be corrected by vaccination. Together, our results reveal several surprising aspects of antitumor immunity and have implications for cancer vaccine design."}